A ‘fit’ microbiota to potentiate cancer immunotherapy
Open Access
- 21 December 2015
- journal article
- research article
- Published by Springer Nature in Genome Medicine
- Vol. 7 (1) , 1-2
Abstract
Cancer immunotherapy is very effective and leads to a long-term response in certain patients. Yet, the variability observed in this response indicates that additional factors related to the host must influence the activity of the treatments. Recent research suggests that the microbiota might play an important part in this variability.Keywords
Funding Information
- European Research Council (HomeoGUT)
- Associazione Italiana per la Ricerca sul Cancro
- Ministero della Salute (Ricerca Finalizzata)
This publication has 10 references indexed in Scilit:
- Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiotaScience, 2015
- Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacyScience, 2015
- BALB/c and C57BL/6 Mice Differ in Polyreactive IgA Abundance, which Impacts the Generation of Antigen-Specific IgA and Microbiota DiversityImmunity, 2015
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated MelanomaNew England Journal of Medicine, 2015
- Dynamics and Stabilization of the Human Gut Microbiome during the First Year of LifeCell Host & Microbe, 2015
- The Intestinal Microbiota Modulates the Anticancer Immune Effects of CyclophosphamideScience, 2013
- Commensal Bacteria Control Cancer Response to Therapy by Modulating the Tumor MicroenvironmentScience, 2013
- Interactions Between the Microbiota and the Immune SystemScience, 2012
- Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newbornsProceedings of the National Academy of Sciences, 2010
- A human gut microbial gene catalogue established by metagenomic sequencingNature, 2010